The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Drug Manufacturers - Other > Anthra Pharmaceuticals, Inc.

Anthra Pharmaceuticals, Inc.
 PROFILE
Anthra Pharmaceuticals has discovered a new pharmaceutical star -- its Valstar bladder cancer treatment. The company acquires and develops late-stage drug candidates that treat a variety of cancers. Anthra has licensed Valstar -- which was approved by the Food and Drug Administration in 1998 -- to Medeva (now part of the Celltech Group) for sale in the US; to Amersham (formerly Nycomed Amersham) for sale in Europe (where the drug is awaiting approval); and to Paladin Labs for sale in Canada (where it received approval in 2000 and is marketed as Valtaxin). Anthra Pharmaceuticals' patent for Valstar expires in 2003. The company withdrew its IPO in early 1999.

 COMPETITION
Corixa Corporation (CRXA)
SuperGen, Inc. (SUPG)

 FINANCIAL OVERVIEW
Fiscal Year-End: June
1998 Sales (mil.): 0.00
Employees: 33
Revenue per employee: $0.00

 KEY PEOPLE
• Michael C. Walker
    CEO
• Michael C. Walker
    CFO

 CONTACT INFO
103 Carnegie Center, Ste. 102
Princeton, NJ 08540
US
Phone: 609-924-2680
Fax: 609-924-3875
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001